Efficacy and Safety of Bempedoic Acid in Japanese Patients With Hypercholesterolemia - A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (the CLEAR-J Trial).
Yamashita S, Kiyosue A, Fujita H, Yokota D, Nakamura Y, Yasuda S.
Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial.
Shao C, Zhang S, Cheng Z, Yang K, Wang G, Shi X, Yang H, Ji Y, Li H, Zhang S, Ma J, Pei Z, Zhang Y, Li Y, Li L, Zheng Y, Shao C, Zhang M, Hao Y, Tang YD.
Atherosclerosis. 2025 Aug;407:120408. doi: 10.1016/j.atherosclerosis.2025.120408. Epub 2025 Jun 16.
PMID:40543299
Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials.
Qi L, Shen H, Chai M, Chen B, He Y, Shi X, Lian Q, Zhao W, Qu Y, Qian L, Zhang J, Li H, Zhou Y, Huo Y.
Familial hypercholesterolemia in Chinese children and adolescents: a multicenter study.
Huang MN, Wang CC, Ma MS, Chi MZ, Zhou Q, Jiang LH, Wang CL, Lu M, Chen XQ, Cheng YY, Ke Q, Wang DY, Qian XX, Ying XM, Zhang JP, Shen QH, Liu LF, Gu R, Zhang ZJ, Feng JH, Wang M, Zhu MQ, Huang K, Fu JF, Zou CC.
Lipids Health Dis. 2024 Dec 27;23(1):423. doi: 10.1186/s12944-024-02406-4.
PMID:39731075
The clinical utility of polygenic risk scores for combined hyperlipidemia.